The National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) intends to award a firm-fixed price sole source contract to:
Adaptive Biotechnologies
1551 Eastlake Ave E, Ste 200
Seattle, WA 98102
For:
Qty 30 of catalog#ISS22000-ImmunoSEQ hsTCRB v4 Service (Deep)-Academic RUO
Qty 90 of catalog#ADS00000-DNA Extraction Service-immunoSEQ
Qty 60 of catalog#ISS12000-ImmunoSEQ hsTCRB v4 Service (Survey) - Academic RUO
Qty 38 of catalog#ISS10000-ImmunoSEQ hsTCRB Service (Survey)
Shipping, handling charges.
Place of Performance:
NATIONAL INSTITUTES OF HEALTH
The associated North American Industry Classification System (NAICS) code for this procurement is 543180 with a small business size standard of 1250. Adaptive Biotechnologies Corporation is a small business.
This will be the only notice of the Government's intent to solicit, negotiate, and award to one source to satisfy this requirement. The Government plans to award a contract for this requirement within 30 days of this notice.
While this synopsis does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy this requirement. The Government understands that Adaptive Biotechnologies Corporation is the only vendor which can provide the requested supplies for NIAID. However, firms that believe they can provide the capability required to fully meet the Government's requirement may submit a capability statement, proposal or quotation that will be considered by this Agency in writing to the identified point of contact within ten (10) days after publication of this notice. Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Interested parties may identify their interest and capability to respond to the requirement or submit offers on NOI-RML-1922257
For additional information or to submit responses, please contact Michael Barrett; (E-Mail/ [email protected]).